A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants

A Single-blind, Multi-center, Randomized, Active-controlled, Parallel Group, Phase II Study to Evaluate the Safety and Immunogenicity of Intramuscular Three Injections With LBVE(Multivalent Pneumococcal Conjugate Vaccine) Compared to Prevnar13 in Healthy Infants

The purpose of this study is to evaluate the safety and immunogenicity of LBVE (Multivalent Pneumococcal Conjugate Vaccine) in healthy infants.

Inclusion Criteria:

• Healthy infants of either sex who have reached at least 42 days (6 weeks) of age and not more than 56 days (8 weeks) of age at the time of enrollment.
• The parents or LAR(Legally authorized representative) able to understand and comply with planned study procedures.
• Signed informed consent by subject's parents or LAR(Legally authorized representative)

Exclusion Criteria:

• Previously received any pneumococcal vaccine
• Receipt of immunoglobulin or blood-derived product before the study
• Known or suspected immune disorder, or received immunosuppressive therapy
• Known major congenital malformation or serious chronic disorder
• Participation in another interventional trial